Last reviewed · How we verify

Platelet Rich Plasma

Wroclaw Medical University · FDA-approved active Small molecule Quality 5/100

Platelet Rich Plasma (PRP) is a marketed product developed by Wroclaw Medical University, currently without a specified primary indication or revenue data. A key strength of PRP is its patent protection, which extends until 2028, providing a barrier to generic competition. The primary risk is the lack of detailed clinical trial results and identified competitors, which may affect market confidence and adoption.

At a glance

Generic namePlatelet Rich Plasma
Also known asPRP, Plasma, Platelet Rich, Blood Platelets, PRP Injection, Platelet Concentrate
SponsorWroclaw Medical University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: